Thu, March 11, 2021
Wed, March 10, 2021
Tue, March 9, 2021

Difei Yang Upgraded (BLUE) to Strong Buy and Increased Target to $69 on, Mar 10th, 2021

Difei Yang of Mizuho, Upgraded "bluebird bio, Inc." (BLUE) to Strong Buy and Increased Target from $34 to $69 on, Mar 10th, 2021.

Difei has made no other calls on BLUE in the last 4 months.



There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, 2 agree with Difei's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $45 on, Tuesday, March 2nd, 2021
  • Cory Kasimov of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $39 on, Wednesday, February 17th, 2021


This is the rating of the analyst that currently disagrees with Difei


  • Yun Zhong of "Berenberg" Initiated at Strong Buy and Held Target at $64 on, Wednesday, November 11th, 2020